Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Vet Intern Med ; 37(5): 1839-1847, 2023.
Article in English | MEDLINE | ID: mdl-37522795

ABSTRACT

BACKGROUND: Vitamin E has a positive effect in the management of osteoarthritis in humans, and in a previous study of dogs. It has been suggested to decrease C-reactive protein concentrations and liver enzyme activities in humans and animals. OBJECTIVE: To assess the effect of vitamin E supplementation on lameness, pain, pain medication requirement, clinical pathology variables, and quality of life in large-breed dogs with naturally occurring osteoarthritis. ANIMALS: Fifty-seven client-owned dogs with naturally occurring osteoarthritis. METHODS: Dogs received either vitamin E or placebo for 90 days in a randomized, placebo-controlled, double-blinded, prospective clinical trial. Clinical lameness scores, pain medication requirements, and owner questionnaires were used to assess response to treatment every 30 days. Blood samples were collected at enrollment and at the end of the study period. RESULTS: Vitamin E administration did not improve pain, lameness, or quality of life as assessed by owners and veterinarians. Vitamin E supplementation did not decrease the requirement for rescue pain relief. No changes in clinical pathology variables were observed after 90 days of vitamin E supplementation. Body weight was negatively associated with the lameness scores and requirement for rescue pain relief. CONCLUSION: Vitamin E supplementation did not have any observable positive effects in dogs with naturally occurring osteoarthritis.


Subject(s)
Dog Diseases , Osteoarthritis , Animals , Dogs , Dietary Supplements , Dog Diseases/drug therapy , Lameness, Animal/drug therapy , Osteoarthritis/drug therapy , Osteoarthritis/veterinary , Pain/drug therapy , Pain/veterinary , Prospective Studies , Animal Welfare
2.
PLoS One ; 18(2): e0281876, 2023.
Article in English | MEDLINE | ID: mdl-36809290

ABSTRACT

Neurofibromatosis Type 2 is an inherited disease characterized by Schwann cell tumors of cranial and peripheral nerves. The NF2 gene encodes Merlin, a member of the ERM family consisting of an N-terminal FERM domain, a central α-helical region, and a C-terminal domain. Changes in the intermolecular FERM-CTD interaction allow Merlin to transition between an open, FERM accessible conformation and a closed, FERM-inaccessible conformation, modulating Merlin activity. Merlin has been shown to dimerize, but the regulation and function Merlin dimerization is not clear. We used a nanobody based binding assay to show that Merlin dimerizes via a FERM-FERM interaction, orientated with each C-terminus close to each other. Patient derived and structural mutants show that dimerization controls interactions with specific binding partners, including HIPPO pathway components, and correlates with tumor suppressor activity. Gel filtration experiments showed that dimerization occurs after a PIP2 mediated transition from closed to open conformation monomers. This process requires the first 18 amino acids of the FERM domain and is inhibited by phosphorylation at serine 518. The discovery that active, open conformation Merlin is a dimer represents a new paradigm for Merlin function with implications for the development of therapies designed to compensate for Merlin loss.


Subject(s)
Genes, Neurofibromatosis 2 , Neurofibromin 2 , Humans , Dimerization , Genes, Tumor Suppressor , Neurofibromin 2/genetics , Protein Structure, Tertiary , Protein Multimerization
3.
Oncogene ; 40(24): 4229-4241, 2021 06.
Article in English | MEDLINE | ID: mdl-34079083

ABSTRACT

Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas that cause significant mortality in adults with neurofibromatosis type 1. We compared gene expression of growth factors in normal human nerves to MPNST and normal human Schwann cells to MPNST cell lines. We identified WNT5A as the most significantly upregulated ligand-coding gene and verified its protein expression in MPNST cell lines and tumors. In many contexts WNT5A acts as an oncogene. However, inhibiting WNT5A expression using shRNA did not alter MPNST cell proliferation, invasion, migration, or survival in vitro. Rather, shWNT5A-treated MPNST cells upregulated mRNAs associated with the remodeling of extracellular matrix and with immune cell communication. In addition, these cells secreted increased amounts of the proinflammatory cytokines CXCL1, CCL2, IL6, CXCL8, and ICAM1. Versus controls, shWNT5A-expressing MPNST cells formed larger tumors in vivo. Grafted tumors contained elevated macrophage/stromal cells, larger and more numerous blood vessels, and increased levels of Mmp9, Cxcl13, Lipocalin-1, and Ccl12. In some MPNST settings, these effects were mimicked by targeting the WNT5A receptor ROR2. These data suggest that the non-canonical Wnt ligand WNT5A inhibits MPNST tumor formation by modulating the MPNST microenvironment, so that blocking WNT5A accelerates tumor growth in vivo.


Subject(s)
Cell Proliferation/genetics , Nerve Sheath Neoplasms/genetics , Tumor Microenvironment/genetics , Wnt-5a Protein/genetics , Cell Line, Tumor , Cell Movement/genetics , Extracellular Matrix/genetics , Humans , Nerve Sheath Neoplasms/pathology , Neurofibromatosis 1/genetics , Neurofibromatosis 1/pathology , Neurofibrosarcoma/genetics , Neurofibrosarcoma/pathology , RNA, Messenger/genetics , RNA, Small Interfering/genetics , Schwann Cells/pathology
4.
Sensors (Basel) ; 19(22)2019 Nov 12.
Article in English | MEDLINE | ID: mdl-31726741

ABSTRACT

The hotspot issue in wireless sensor networks, with nodes nearest the sink node losing energy fastest and degrading network lifetime, is a well-referenced problem. Mobile sink nodes have been proposed as a solution to this. They do not completely remove the hotspot problem though, with nodes the sink passes most closely still expending more energy than others. This study proposes a lightweight algorithm, located in the media access control (MAC) layer of static nodes and utilising knowledge of predictable sink node mobility. This is in order to create a dynamic communication threshold between static nodes and the sink, within which static nodes awaken, lessening competition for sink communication between nodes. In utilising predictable mobility and factors already known to the static node, such as location and interference range, there is no need for energy-consuming messaging. Analysis and simulation results, tested on a lightweight implementation of a carrier-sense multiple-access-based MAC protocol, show a significant improvement in energy consumption in both controlled and random environments, with frame delivery improved to the point where sink speed is negated. This is when compared to the existing duty cycling approach.

5.
Acta Neuropathol Commun ; 6(1): 127, 2018 11 23.
Article in English | MEDLINE | ID: mdl-30470263

ABSTRACT

Normal Schwann cells (SCs) are quiescent in adult nerves, when ATP is released from the nerve in an activity dependent manner. We find that suppressing nerve activity in adult nerves causes SC to enter the cell cycle. In vitro, ATP activates the SC G-protein coupled receptor (GPCR) P2Y2. Downstream of P2Y2, ß-arrestin-mediated signaling results in PP2-mediated de-phosphorylation of AKT, and PP2 activity is required for SC growth suppression. NF1 deficient SC show reduced growth suppression by ATP, and are resistant to the effects of ß-arrestin-mediated signaling, including PP2-mediated de-phosphorylation of AKT. In patients with the disorder Neurofibromatosis type 1, NF1 mutant SCs proliferate and form SC tumors called neurofibromas. Elevating ATP levels in vivo reduced neurofibroma cell proliferation. Thus, the low proliferation characteristic of differentiated adult peripheral nerve may require ongoing, nerve activity-dependent, ATP. Additionally, we identify a mechanism through which NF1 SCs may evade growth suppression in nerve tumors.


Subject(s)
Adenosine Triphosphate/metabolism , Arrestin/metabolism , Neurofibromin 1/deficiency , Neuroglia/metabolism , Protein Phosphatase 2/metabolism , Sciatic Nerve/cytology , Animals , Bupivacaine/pharmacology , Calcium/metabolism , Cells, Cultured , Embryo, Mammalian , Ganglia, Spinal/cytology , Humans , Hydroxides/pharmacology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neurofibromin 1/genetics , Neuroglia/drug effects , Neurons/drug effects , Neurons/metabolism , Pain Measurement , Sciatic Neuropathy , Sodium Channel Blockers/pharmacology , Tetrodotoxin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...